CGC — Canopy Growth Corporation
NASDAQ
Q3 2026 Earnings Call Summary
February 6, 2026
Summary of Canopy Growth's Q3 Fiscal 2026 Earnings Call
1. Key Financial Results and Metrics
- Cash Position: Ended Q3 with CAD 371 million in cash and cash equivalents, and a net cash position of CAD 146 million.
- Adjusted EBITDA: Narrowed adjusted EBITDA loss to CAD 3 million, the smallest loss to date.
- Net Revenue: Total cannabis net revenue reached CAD 52 million, up 4% year-over-year.
- Medical Cannabis: Revenue increased 15% year-over-year to CAD 23 million.
- Adult-Use Cannabis: Revenue rose 8% year-over-year to CAD 23 million.
- Gross Margin: Cannabis gross margin at 25%, down from 28% year-over-year.
- Free Cash Flow: Outflow of CAD 19 million, improved from CAD 28 million in the previous year.
2. Strategic Updates and Business Highlights
- Acquisition of MTL Cannabis: Proposed acquisition expected to enhance Canopy's market position in Canadian medical cannabis and adult-use sectors, providing high-quality flower supply.
- Cost-Saving Initiatives: Achieved CAD 29 million in annualized savings, exceeding expectations.
- International Business: Stabilization efforts led to a 22% sequential revenue increase; focus on EU GMP certification to enhance international supply capabilities.
- Storz & Bickel Performance: Revenue grew 45% sequentially, driven by new product launches and seasonal sales.
3. Forward Guidance and Outlook
- Positive Adjusted EBITDA: Targeting to achieve positive adjusted EBITDA during fiscal 2027, with expectations for improved cannabis gross margins.
- Growth in Canadian Markets: Anticipating continued strength in both medical and adult-use segments, driven by innovation and enhanced distribution.
- International Expansion: Plans to leverage MTL's capabilities to boost international market presence, particularly in Europe.
4. Bad News, Challenges, or Points of Concern
- Veterans Reimbursement Program: Proposed reduction in reimbursement rates for veterans poses a risk to the medical cannabis segment, which is significantly reliant on this market.
- Gross Margin Pressures: Decline in gross margins attributed to lower international sales and changes in product mix within the Canadian adult-use market.
- Market Volatility: Ongoing challenges in the cannabis market, including regulatory changes and competitive pressures.
5. Notable Q&A Insights
- International Growth: Luc Mongeau emphasized the importance of flower supply for European markets, indicating plans to significantly increase the variety of strains available.
- MTL Integration Costs: Estimated integration costs for MTL acquisition to be between CAD 40 million and CAD 50 million.
- Veterans Market Size: Clarification on the veterans' segment being a significant portion of the medical market, with ongoing efforts to mitigate potential impacts from reimbursement changes.
- Storz & Bickel Strategy: Focus on expanding market penetration and product innovation to stabilize and grow sales, particularly in the U.S. market.
Overall, Canopy Growth demonstrated progress in financial performance and strategic initiatives, while facing challenges related to regulatory changes and market dynamics. The company remains focused on achieving positive adjusted EBITDA and leveraging acquisitions for future growth.